KORU Medical Systems, Inc. (KRMD) Stock Competitors & Peer Comparison
See (KRMD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KRMD | $3.99 | +1.53% | 183.3M | -79.80 | -$0.05 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.33% |
| BDX | $149.99 | -0.77% | 54.3B | 26.17 | $5.73 | +2.33% |
| ALC | $66.11 | -1.04% | 32.2B | 39.58 | $1.67 | +0.54% |
| MDLN | $33.80 | +0.57% | 28.6B | 29.65 | $1.14 | N/A |
| WST | $319.75 | +1.67% | 22.6B | 42.70 | $7.49 | +0.27% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.33% |
| COO | $66.79 | -0.82% | 13B | 33.23 | $2.01 | N/A |
| BAX | $19.24 | -0.72% | 9.9B | -10.07 | -$1.91 | +1.04% |
Stock Comparison
KRMD vs BDXA Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, KRMD is priced at $3.99, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas BDXA's P/E ratio is 21.44. In terms of profitability, KRMD's ROE is -0.14%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, KRMD is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check BDXA's competition here
KRMD vs BDX Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, BDX has a market cap of 54.3B. Regarding current trading prices, KRMD is priced at $3.99, while BDX trades at $149.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas BDX's P/E ratio is 26.17. In terms of profitability, KRMD's ROE is -0.14%, compared to BDX's ROE of +0.05%. Regarding short-term risk, KRMD is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check BDX's competition here
KRMD vs ALC Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, ALC has a market cap of 32.2B. Regarding current trading prices, KRMD is priced at $3.99, while ALC trades at $66.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas ALC's P/E ratio is 39.58. In terms of profitability, KRMD's ROE is -0.14%, compared to ALC's ROE of +0.04%. Regarding short-term risk, KRMD is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check ALC's competition here
KRMD vs MDLN Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, MDLN has a market cap of 28.6B. Regarding current trading prices, KRMD is priced at $3.99, while MDLN trades at $33.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas MDLN's P/E ratio is 29.65. In terms of profitability, KRMD's ROE is -0.14%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, KRMD is less volatile compared to MDLN. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check MDLN's competition here
KRMD vs WST Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, WST has a market cap of 22.6B. Regarding current trading prices, KRMD is priced at $3.99, while WST trades at $319.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas WST's P/E ratio is 42.70. In terms of profitability, KRMD's ROE is -0.14%, compared to WST's ROE of +0.18%. Regarding short-term risk, KRMD is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check WST's competition here
KRMD vs HOLX Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, KRMD is priced at $3.99, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas HOLX's P/E ratio is 31.54. In terms of profitability, KRMD's ROE is -0.14%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, KRMD is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check HOLX's competition here
KRMD vs BDXB Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, KRMD is priced at $3.99, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas BDXB's P/E ratio is 7.60. In terms of profitability, KRMD's ROE is -0.14%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, KRMD is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check BDXB's competition here
KRMD vs COO Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, COO has a market cap of 13B. Regarding current trading prices, KRMD is priced at $3.99, while COO trades at $66.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas COO's P/E ratio is 33.23. In terms of profitability, KRMD's ROE is -0.14%, compared to COO's ROE of +0.03%. Regarding short-term risk, KRMD is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check COO's competition here
KRMD vs BAX Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, BAX has a market cap of 9.9B. Regarding current trading prices, KRMD is priced at $3.99, while BAX trades at $19.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas BAX's P/E ratio is -10.07. In terms of profitability, KRMD's ROE is -0.14%, compared to BAX's ROE of -0.16%. Regarding short-term risk, KRMD is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check BAX's competition here
KRMD vs ATR Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, ATR has a market cap of 7.2B. Regarding current trading prices, KRMD is priced at $3.99, while ATR trades at $111.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas ATR's P/E ratio is 19.19. In terms of profitability, KRMD's ROE is -0.14%, compared to ATR's ROE of +0.14%. Regarding short-term risk, KRMD is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check ATR's competition here
KRMD vs RGEN Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, RGEN has a market cap of 7.1B. Regarding current trading prices, KRMD is priced at $3.99, while RGEN trades at $125.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas RGEN's P/E ratio is 137.73. In terms of profitability, KRMD's ROE is -0.14%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, KRMD is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check RGEN's competition here
KRMD vs AVTR Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, AVTR has a market cap of 6.6B. Regarding current trading prices, KRMD is priced at $3.99, while AVTR trades at $9.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas AVTR's P/E ratio is -11.96. In terms of profitability, KRMD's ROE is -0.14%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, KRMD is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check AVTR's competition here
KRMD vs TFX Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, KRMD is priced at $3.99, while TFX trades at $131.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas TFX's P/E ratio is 2196.08. In terms of profitability, KRMD's ROE is -0.14%, compared to TFX's ROE of -0.28%. Regarding short-term risk, KRMD is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check TFX's competition here
KRMD vs BLCO Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, BLCO has a market cap of 5.4B. Regarding current trading prices, KRMD is priced at $3.99, while BLCO trades at $15.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas BLCO's P/E ratio is -24.47. In terms of profitability, KRMD's ROE is -0.14%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, KRMD is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check BLCO's competition here
KRMD vs STVN Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, STVN has a market cap of 4.9B. Regarding current trading prices, KRMD is priced at $3.99, while STVN trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas STVN's P/E ratio is 30.53. In terms of profitability, KRMD's ROE is -0.14%, compared to STVN's ROE of +0.10%. Regarding short-term risk, KRMD is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check STVN's competition here
KRMD vs MMSI Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, MMSI has a market cap of 3.9B. Regarding current trading prices, KRMD is priced at $3.99, while MMSI trades at $66.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas MMSI's P/E ratio is 28.46. In terms of profitability, KRMD's ROE is -0.14%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, KRMD is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check MMSI's competition here
KRMD vs ICUI Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, ICUI has a market cap of 3.4B. Regarding current trading prices, KRMD is priced at $3.99, while ICUI trades at $137.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas ICUI's P/E ratio is 73.91. In terms of profitability, KRMD's ROE is -0.14%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, KRMD is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check ICUI's competition here
KRMD vs HAE Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, HAE has a market cap of 3.4B. Regarding current trading prices, KRMD is priced at $3.99, while HAE trades at $74.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas HAE's P/E ratio is 36.54. In terms of profitability, KRMD's ROE is -0.14%, compared to HAE's ROE of +0.11%. Regarding short-term risk, KRMD is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check HAE's competition here
KRMD vs WRBY Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, WRBY has a market cap of 2.9B. Regarding current trading prices, KRMD is priced at $3.99, while WRBY trades at $23.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas WRBY's P/E ratio is 2350.00. In terms of profitability, KRMD's ROE is -0.14%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, KRMD is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check WRBY's competition here
KRMD vs LMAT Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, KRMD is priced at $3.99, while LMAT trades at $95.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas LMAT's P/E ratio is 34.97. In terms of profitability, KRMD's ROE is -0.14%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, KRMD is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check LMAT's competition here
KRMD vs XRAY Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, XRAY has a market cap of 2.1B. Regarding current trading prices, KRMD is priced at $3.99, while XRAY trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas XRAY's P/E ratio is -3.26. In terms of profitability, KRMD's ROE is -0.14%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, KRMD is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check XRAY's competition here
KRMD vs NVCR Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, KRMD is priced at $3.99, while NVCR trades at $16.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas NVCR's P/E ratio is -11.01. In terms of profitability, KRMD's ROE is -0.14%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, KRMD is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check NVCR's competition here
KRMD vs PLSE Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, PLSE has a market cap of 1.7B. Regarding current trading prices, KRMD is priced at $3.99, while PLSE trades at $24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas PLSE's P/E ratio is -22.58. In terms of profitability, KRMD's ROE is -0.14%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, KRMD is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check PLSE's competition here
KRMD vs STAA Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, STAA has a market cap of 1.5B. Regarding current trading prices, KRMD is priced at $3.99, while STAA trades at $29.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas STAA's P/E ratio is -71.33. In terms of profitability, KRMD's ROE is -0.14%, compared to STAA's ROE of -0.06%. Regarding short-term risk, KRMD is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check STAA's competition here
KRMD vs ATRC Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, ATRC has a market cap of 1.4B. Regarding current trading prices, KRMD is priced at $3.99, while ATRC trades at $26.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas ATRC's P/E ratio is -269.15. In terms of profitability, KRMD's ROE is -0.14%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, KRMD is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check ATRC's competition here
KRMD vs BLFS Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, BLFS has a market cap of 1.3B. Regarding current trading prices, KRMD is priced at $3.99, while BLFS trades at $26.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas BLFS's P/E ratio is -108.75. In terms of profitability, KRMD's ROE is -0.14%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, KRMD is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check BLFS's competition here
KRMD vs KMTS Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, KRMD is priced at $3.99, while KMTS trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas KMTS's P/E ratio is -3.62. In terms of profitability, KRMD's ROE is -0.14%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, KRMD is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check KMTS's competition here
KRMD vs AZTA Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, AZTA has a market cap of 1B. Regarding current trading prices, KRMD is priced at $3.99, while AZTA trades at $22.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas AZTA's P/E ratio is -9.42. In terms of profitability, KRMD's ROE is -0.14%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, KRMD is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check AZTA's competition here
KRMD vs QDEL Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, QDEL has a market cap of 986.4M. Regarding current trading prices, KRMD is priced at $3.99, while QDEL trades at $14.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas QDEL's P/E ratio is -0.81. In terms of profitability, KRMD's ROE is -0.14%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, KRMD is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check QDEL's competition here
KRMD vs ATRI Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, KRMD is priced at $3.99, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas ATRI's P/E ratio is 64.50. In terms of profitability, KRMD's ROE is -0.14%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, KRMD is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check ATRI's competition here
KRMD vs NNNN Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, NNNN has a market cap of 755.8M. Regarding current trading prices, KRMD is priced at $3.99, while NNNN trades at $17.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas NNNN's P/E ratio is 114.80. In terms of profitability, KRMD's ROE is -0.14%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, KRMD is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check NNNN's competition here
KRMD vs ANGO Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, ANGO has a market cap of 492.9M. Regarding current trading prices, KRMD is priced at $3.99, while ANGO trades at $11.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas ANGO's P/E ratio is -15.70. In terms of profitability, KRMD's ROE is -0.14%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, KRMD is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check ANGO's competition here
KRMD vs OSUR Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, OSUR has a market cap of 285.7M. Regarding current trading prices, KRMD is priced at $3.99, while OSUR trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas OSUR's P/E ratio is -3.95. In terms of profitability, KRMD's ROE is -0.14%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, KRMD is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check OSUR's competition here
KRMD vs UTMD Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, UTMD has a market cap of 213.5M. Regarding current trading prices, KRMD is priced at $3.99, while UTMD trades at $67.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas UTMD's P/E ratio is 19.84. In terms of profitability, KRMD's ROE is -0.14%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, KRMD is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check UTMD's competition here
KRMD vs PDEX Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, PDEX has a market cap of 207.5M. Regarding current trading prices, KRMD is priced at $3.99, while PDEX trades at $65.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas PDEX's P/E ratio is 17.91. In terms of profitability, KRMD's ROE is -0.14%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, KRMD is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check PDEX's competition here
KRMD vs SMTI Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, SMTI has a market cap of 202.4M. Regarding current trading prices, KRMD is priced at $3.99, while SMTI trades at $22.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas SMTI's P/E ratio is 368.17. In terms of profitability, KRMD's ROE is -0.14%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, KRMD is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check SMTI's competition here
KRMD vs INFU Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, INFU has a market cap of 182M. Regarding current trading prices, KRMD is priced at $3.99, while INFU trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas INFU's P/E ratio is 24.38. In terms of profitability, KRMD's ROE is -0.14%, compared to INFU's ROE of +0.14%. Regarding short-term risk, KRMD is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check INFU's competition here
KRMD vs STXS Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, STXS has a market cap of 175.9M. Regarding current trading prices, KRMD is priced at $3.99, while STXS trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas STXS's P/E ratio is -7.50. In terms of profitability, KRMD's ROE is -0.14%, compared to STXS's ROE of -1.53%. Regarding short-term risk, KRMD is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check STXS's competition here
KRMD vs MBOT Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, MBOT has a market cap of 82.9M. Regarding current trading prices, KRMD is priced at $3.99, while MBOT trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas MBOT's P/E ratio is -7.00. In terms of profitability, KRMD's ROE is -0.14%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, KRMD is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check MBOT's competition here
KRMD vs AKYA Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, KRMD is priced at $3.99, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas AKYA's P/E ratio is -1.34. In terms of profitability, KRMD's ROE is -0.14%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, KRMD is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check AKYA's competition here
KRMD vs STSS Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, STSS has a market cap of 55.2M. Regarding current trading prices, KRMD is priced at $3.99, while STSS trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas STSS's P/E ratio is -0.02. In terms of profitability, KRMD's ROE is -0.14%, compared to STSS's ROE of -1.66%. Regarding short-term risk, KRMD is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check STSS's competition here
KRMD vs ZTEK Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, ZTEK has a market cap of 53.4M. Regarding current trading prices, KRMD is priced at $3.99, while ZTEK trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas ZTEK's P/E ratio is -8.28. In terms of profitability, KRMD's ROE is -0.14%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, KRMD is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check ZTEK's competition here
KRMD vs NYXH Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, NYXH has a market cap of 51.9M. Regarding current trading prices, KRMD is priced at $3.99, while NYXH trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas NYXH's P/E ratio is -0.56. In terms of profitability, KRMD's ROE is -0.14%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, KRMD is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check NYXH's competition here
KRMD vs OMIC Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, KRMD is priced at $3.99, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas OMIC's P/E ratio is -0.58. In terms of profitability, KRMD's ROE is -0.14%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, KRMD is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check OMIC's competition here
KRMD vs DXR Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, DXR has a market cap of 50.2M. Regarding current trading prices, KRMD is priced at $3.99, while DXR trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas DXR's P/E ratio is 6.08. In terms of profitability, KRMD's ROE is -0.14%, compared to DXR's ROE of +0.22%. Regarding short-term risk, KRMD is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check DXR's competition here
KRMD vs IGAP Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, KRMD is priced at $3.99, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas IGAP's P/E ratio is -10.52. In terms of profitability, KRMD's ROE is -0.14%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, KRMD is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check IGAP's competition here
KRMD vs POCI Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, POCI has a market cap of 43.4M. Regarding current trading prices, KRMD is priced at $3.99, while POCI trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas POCI's P/E ratio is -8.78. In terms of profitability, KRMD's ROE is -0.14%, compared to POCI's ROE of -0.37%. Regarding short-term risk, KRMD is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check POCI's competition here
KRMD vs NEPH Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, NEPH has a market cap of 36.8M. Regarding current trading prices, KRMD is priced at $3.99, while NEPH trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas NEPH's P/E ratio is 48.43. In terms of profitability, KRMD's ROE is -0.14%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, KRMD is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check NEPH's competition here
KRMD vs MLSS Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, MLSS has a market cap of 34M. Regarding current trading prices, KRMD is priced at $3.99, while MLSS trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas MLSS's P/E ratio is -6.43. In terms of profitability, KRMD's ROE is -0.14%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, KRMD is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check MLSS's competition here
KRMD vs SDC Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, KRMD is priced at $3.99, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas SDC's P/E ratio is -0.03. In terms of profitability, KRMD's ROE is -0.14%, compared to SDC's ROE of -1.96%. Regarding short-term risk, KRMD is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check SDC's competition here
KRMD vs EKSO Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, EKSO has a market cap of 28.6M. Regarding current trading prices, KRMD is priced at $3.99, while EKSO trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas EKSO's P/E ratio is -2.31. In terms of profitability, KRMD's ROE is -0.14%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, KRMD is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check EKSO's competition here
KRMD vs HBIO Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, HBIO has a market cap of 27.1M. Regarding current trading prices, KRMD is priced at $3.99, while HBIO trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas HBIO's P/E ratio is -2.80. In terms of profitability, KRMD's ROE is -0.14%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, KRMD is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check HBIO's competition here
KRMD vs IVC Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, KRMD is priced at $3.99, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas IVC's P/E ratio is -0.79. In terms of profitability, KRMD's ROE is -0.14%, compared to IVC's ROE of -0.46%. Regarding short-term risk, KRMD is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check IVC's competition here
KRMD vs RVP Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, RVP has a market cap of 20.7M. Regarding current trading prices, KRMD is priced at $3.99, while RVP trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas RVP's P/E ratio is -3.14. In terms of profitability, KRMD's ROE is -0.14%, compared to RVP's ROE of -0.08%. Regarding short-term risk, KRMD is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check RVP's competition here
KRMD vs FEMY Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, FEMY has a market cap of 19M. Regarding current trading prices, KRMD is priced at $3.99, while FEMY trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas FEMY's P/E ratio is -1.12. In terms of profitability, KRMD's ROE is -0.14%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, KRMD is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check FEMY's competition here
KRMD vs ZJYL Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, ZJYL has a market cap of 17.2M. Regarding current trading prices, KRMD is priced at $3.99, while ZJYL trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas ZJYL's P/E ratio is 11.00. In terms of profitability, KRMD's ROE is -0.14%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, KRMD is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check ZJYL's competition here
KRMD vs ARTC Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, ARTC has a market cap of 16.1M. Regarding current trading prices, KRMD is priced at $3.99, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas ARTC's P/E ratio is N/A. In terms of profitability, KRMD's ROE is -0.14%, compared to ARTC's ROE of N/A. Regarding short-term risk, KRMD is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check ARTC's competition here
KRMD vs RGNT Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, RGNT has a market cap of 5.1M. Regarding current trading prices, KRMD is priced at $3.99, while RGNT trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas RGNT's P/E ratio is -0.05. In terms of profitability, KRMD's ROE is -0.14%, compared to RGNT's ROE of N/A. Regarding short-term risk, KRMD is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check RGNT's competition here
KRMD vs NSTG Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, KRMD is priced at $3.99, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas NSTG's P/E ratio is -0.03. In terms of profitability, KRMD's ROE is -0.14%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, KRMD is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check NSTG's competition here
KRMD vs NXGL Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, NXGL has a market cap of 5M. Regarding current trading prices, KRMD is priced at $3.99, while NXGL trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas NXGL's P/E ratio is -1.38. In terms of profitability, KRMD's ROE is -0.14%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, KRMD is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check NXGL's competition here
KRMD vs LUCY Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, LUCY has a market cap of 3.7M. Regarding current trading prices, KRMD is priced at $3.99, while LUCY trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas LUCY's P/E ratio is -0.59. In terms of profitability, KRMD's ROE is -0.14%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, KRMD is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check LUCY's competition here
KRMD vs POAI Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, KRMD is priced at $3.99, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas POAI's P/E ratio is -0.03. In terms of profitability, KRMD's ROE is -0.14%, compared to POAI's ROE of -107.05%. Regarding short-term risk, KRMD is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check POAI's competition here
KRMD vs MHUA Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, KRMD is priced at $3.99, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas MHUA's P/E ratio is 0.25. In terms of profitability, KRMD's ROE is -0.14%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, KRMD is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check MHUA's competition here
KRMD vs NXGLW Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, NXGLW has a market cap of 2.2M. Regarding current trading prices, KRMD is priced at $3.99, while NXGLW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, KRMD's ROE is -0.14%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, KRMD is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check NXGLW's competition here
KRMD vs GMVD Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, KRMD is priced at $3.99, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas GMVD's P/E ratio is -0.01. In terms of profitability, KRMD's ROE is -0.14%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, KRMD is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check GMVD's competition here
KRMD vs GMVDW Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, KRMD is priced at $3.99, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas GMVDW's P/E ratio is N/A. In terms of profitability, KRMD's ROE is -0.14%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, KRMD is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check GMVDW's competition here
KRMD vs AVGR Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, KRMD is priced at $3.99, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas AVGR's P/E ratio is -0.05. In terms of profitability, KRMD's ROE is -0.14%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, KRMD is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check AVGR's competition here
KRMD vs STSSW Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, KRMD is priced at $3.99, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas STSSW's P/E ratio is -0.03. In terms of profitability, KRMD's ROE is -0.14%, compared to STSSW's ROE of +0.12%. Regarding short-term risk, KRMD is less volatile compared to STSSW. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check STSSW's competition here
KRMD vs GCTK Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, GCTK has a market cap of 305.9K. Regarding current trading prices, KRMD is priced at $3.99, while GCTK trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas GCTK's P/E ratio is 0.09. In terms of profitability, KRMD's ROE is -0.14%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, KRMD is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check GCTK's competition here
KRMD vs LUCYW Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, KRMD is priced at $3.99, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas LUCYW's P/E ratio is N/A. In terms of profitability, KRMD's ROE is -0.14%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, KRMD is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check LUCYW's competition here
KRMD vs WOK Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, WOK has a market cap of 571. Regarding current trading prices, KRMD is priced at $3.99, while WOK trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas WOK's P/E ratio is N/A. In terms of profitability, KRMD's ROE is -0.14%, compared to WOK's ROE of -0.07%. Regarding short-term risk, KRMD is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for KRMD.Check WOK's competition here
KRMD vs APR Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, APR has a market cap of 0. Regarding current trading prices, KRMD is priced at $3.99, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas APR's P/E ratio is 22.59. In terms of profitability, KRMD's ROE is -0.14%, compared to APR's ROE of +9.81%. Regarding short-term risk, KRMD is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check APR's competition here
KRMD vs ATRS Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, KRMD is priced at $3.99, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas ATRS's P/E ratio is 14.95. In terms of profitability, KRMD's ROE is -0.14%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, KRMD is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check ATRS's competition here
KRMD vs ALOG Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, KRMD is priced at $3.99, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas ALOG's P/E ratio is N/A. In terms of profitability, KRMD's ROE is -0.14%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, KRMD is more volatile compared to ALOG. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check ALOG's competition here
KRMD vs HRC Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, HRC has a market cap of 0. Regarding current trading prices, KRMD is priced at $3.99, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas HRC's P/E ratio is 41.92. In terms of profitability, KRMD's ROE is -0.14%, compared to HRC's ROE of +0.14%. Regarding short-term risk, KRMD is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check HRC's competition here
KRMD vs IIN Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, IIN has a market cap of 0. Regarding current trading prices, KRMD is priced at $3.99, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas IIN's P/E ratio is 226.45. In terms of profitability, KRMD's ROE is -0.14%, compared to IIN's ROE of -0.00%. Regarding short-term risk, KRMD is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check IIN's competition here
KRMD vs IVTY Comparison June 2026
KRMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRMD stands at 183.3M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, KRMD is priced at $3.99, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRMD currently has a P/E ratio of -79.80, whereas IVTY's P/E ratio is N/A. In terms of profitability, KRMD's ROE is -0.14%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, KRMD is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for KRMD.Check IVTY's competition here